Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
Go back to Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases| (NASDAQ: KYMR) | Delayed: 90.43 +0.53 (0.59%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $89.90 | 52 Week High | $ | |||
| Open | $90.68 | 52 Week Low | $ | |||
| Day High | $92.47 | P/E | N/A | |||
| Day Low | $89.18 | EPS | $ | |||
| Volume | 1,262,295 | |||||
